18 results about "Potassium oxonate" patented technology

The invention discloses a method for constructing a renal injury animal model caused by combination of uric acid crystals and soluble uric acid, which comprises the following steps: applying a urate crystal suspension and a mixed solution of oteracil potassium and uric acid to an experimental animal, the dosage of the urate crystal suspension being 0.5-100mg / kg; the dosage of oteracil potassium per day in the mixed solution of oteracil potassium and uric acid is 750 mg / kg, the dosage of uric acid per day is 300 mg / kg, the dosage of oteracil potassium per day and the dosage of uric acid per day are both calculated according to the weight of the experimental animal, and the application time of the mixed solution of oteracil potassium and uric acid is 3-4 weeks. The invention also discloses the uric acid crystal and soluble uric acid combined renal injury animal model constructed by the method. The method can stably establish an animal kidney injury model caused by increase of soluble uric acid in the kidney and coexistence of urate crystals. And the established model is high in credibility, high in accuracy and universal.

The invention discloses a preeclampsia mouse model. The preeclampsia mouse model is constructed by the following method: (1) combining a female mouse with a male mouse; (2) in the middle stage of pregnancy, intragastric administration of hypoxanthine and oteracil potassium salt is carried out on the pregnant mouse for a period of time; the invention also discloses a construction method and application of the gene. The invention provides a novel preeclampsia modeling mode, hypoxanthine and oteracil potassium salt are combined for use, and the administration dosage and the administration mode of hypoxanthine and oteracil potassium salt are controlled, so that the serum uric acid level of a model mouse is stably increased, preeclampsia change occurs in the model mouse, and the model mouse can be used for treating preeclampsia. The stability, specificity and pathophysiology characteristics of the model are ensured to be similar to those of human preeclampsia, so that the uric acid-induced preeclampsia mouse model is successfully constructed. The uric acid induced preeclampsia mouse model provides a valuable tool for researching the pathogenesis of preeclampsia, evaluating a new treatment method and understanding the effect of serum hyperuricemia in preeclampsia.

The invention discloses a novel application of Wickerhamomyces anomalus YFJ252 (the preservation number is CGMCC (China General Microbiological Culture Collection Center) NO.28267) which is disclosed and preserved, in particular relates to an application of the strain and a metabolite of the strain in preparation of medicines, foods or health care products for preventing or treating hyperuricemia (HUA), and belongs to the technical field of microorganisms. The strain has excellent probiotic characteristics (acid and cholate resistance, high hydrophobicity, self-aggregation and co-aggregation capability, oxidation resistance, glycometabolism regulation, anti-inflammatory capability and the like) and a function of inhibiting the activity of xanthine oxidase (XO) in vitro. The serum uric acid, creatinine and urea nitrogen levels of a hyperuricemia mouse model induced by high fructose diet and oteracil potassium can be remarkably controlled, and a new way is provided for safely and effectively preventing HUA.

The invention provides a method for constructing an animal chronic gouty arthritis model, which comprises the following steps: a hyperuricemia model establishment stage: feeding a tested animal with a special feed containing oteracil potassium and yeast; establishing a chronic gouty arthritis model: repeatedly injecting urate into the tested animal; meanwhile, oteracil potassium is used for intragastric administration of the tested animal. On the basis of feeding with oteracil potassium combined with a special yeast feed, oteracil potassium solution is injected, blood uric acid level fluctuation is induced on the basis of blood uric acid increase, and urate crystals are injected repeatedly, so that the disease cause and pathological process of chronic gouty arthritis are simulated to the greatest extent; a chronic gouty arthritis animal model is successfully established by injecting urate crystals into joints of experimental animals repeatedly for a long time, inducing repeated attack of local acute inflammation of the joints and simulating pathological characteristics of chronic gouty arthritis.

The invention relates to the field of biological medicine, in particular to application of demethyleneberberine in preparation of medicine for preventing or treating gout. In-vitro experiments show that the demethyleneberberine hydrochloride can inhibit RAW264.7 cell inflammation caused by monosodium urate crystals; in-vitro experiments show that the traditional Chinese medicine composition can relieve rat gout-like symptoms induced by MSU and relieve hyperuricemia induced by oteracil potassium combined with hypoxanthine. The result shows that the demethyleneberberine hydrochloride (DMB) can inhibit gout induced by monosodium urate crystals in the aspects of resisting inflammation and regulating uric acid metabolism, and the application range of the demethyleneberberine hydrochloride is widened.

The invention provides a construction method of a hyperuricemia animal model, which comprises the following steps: in a modeling stage, feeding oteracil potassium to an animal, feeding 10-30% of yeast extract feed to simulate high-purine diet, and exposing in a high-temperature and high-humidity environment to obtain the hyperuricemia animal model. According to the method, a high-temperature and high-humidity environment is constructed, the yeast extract feed is fed to simulate high-purine diet, the daily living environment of coastal residents in the south is replied, and on the basis, oteracil potassium administration is combined to eliminate the influence of uricase, so that the method is close to a human uric acid metabolism mode. The animal model obtained by the invention is relatively higher in blood uric acid level, better in stability and small in renal function damage, the animal always keeps a good mental state in the construction process, and the survival rate is 100% after 12 weeks of modeling. The animal model provided by the invention can provide a scientific basis for subsequent research on hyperuricemia pathogenesis and formulation of prevention and treatment measures under special climate and diet environments, and has a good application prospect.

The present application relates to the technical field of hyperuricemia modeling, and particularly relates to a method for inducing and constructing a cynomolgus monkey hyperuricemia model and application thereof, comprising the following steps: S1: selecting male cynomolgus monkeys as model animals; S2: administering an inducing agent to the experimental animals, wherein the inducing agent is composed of hydrochlorothiazide, potassium oxonate and adenine. The inducing agent is added to ordinary monkey feed for normal feeding of the experimental animals, the intake dose of hydrochlorothiazide is 0.1 g / kg / day, the intake dose of potassium oxonate is 0.2 g / kg / day, the intake dose of adenine is 0.1 g / kg / day, and 10% fructose water is used to replace ordinary drinking water at the same time. The present application can induce a stable hyperuricemia state in the cynomolgus monkey body by means of dietary induction, combined use of hydrochlorothiazide, potassium oxonate and adenine, compared with a traditional model induced by a single intraperitoneal injection of a drug, the present application better simulates the pathogenic cause of human hyperuricemia, and is easier to operate.

The invention provides an application of an anacardic acid compound in preparation of an anti-hyperuricemia preparation, and belongs to the technical field of biomedicine.The anacardic acid compound in rhus chinensis fruits is found to be capable of effectively improving oteracil potassium / yeast extract / fructose co-induced HUA through an oteracil potassium / yeast extract / fructose co-induced HUA model, and the application of the anacardic acid compound in the rhus chinensis fruits is found to be capable of improving the hyperuricemia resistance of the rhus chinensis fruits. A new thought is provided for further developing and utilizing the rhus chinensis fruit anacaric acid compound as a medicine for preventing and treating HUA.

The application discloses a hyperuricemia non-human primate model and a construction method thereof, and belongs to the technical field of experimental animals. The construction method comprises the following steps: using a non-human primate, i.e., a cynomolgus monkey, as a model animal, orally administering potassium oxonate and intravenously injecting myo-inositol, so that the blood uric acid content of the cynomolgus monkey is significantly increased within 0.5-8 hours, and the process can be inhibited by a uric acid-lowering drug allopurinol, and based on this, a hyperuricemia model of a non-human primate can be formed. Compared with a model constructed by using rodents, the hyperuricemia non-human primate model constructed by the application can better simulate the related symptoms and physiological processes of human hyperuricemia, and provides a preclinical effect evaluation tool for the research and development of nutrients and drugs in related fields.

Disclosure is a composite mouse model for simulating the exacerbation of periodontitis by hyperuricemia, as well as the establishment methods and applications thereof. The establishment methods includes: intraperitoneally injecting potassium oxonate into a mouse continuously for 7 days to establish a hyperuricemia model; ligating the maxillary second molar of the mouse with a surgical silk thread to construct a periodontitis model; continuously intraperitoneally injecting potassium oxonate into the mouse for another 7 days (days 8 to 14) to establish a composite mouse model that simulates exacerbation of periodontitis by hyperuricemia; continuously intraperitoneally injecting potassium oxonate for 14 days (days 15 to 28) at a fixed frequency once a day to maintain stability of the hyperuricemia model and constructing a stable hyperuricemia compound periodontitis mouse model; and on the 15th day, intraperitoneally injected allopurinol for 14 days continuously to decrease uric acid.

The invention belongs to the technical field of animal model construction, and particularly relates to a hyperuricemia modeling method based on combination of yeast feed and medicine, which comprises the following steps: feeding feed is prepared by mixing the following raw materials in percentage by mass: 30-35% of yeast, 0.1-5% of uric acid inducer and the balance of rat basal feed. Wherein the uric acid inducer is at least one of glucose, ethylenediamine tetraacetic acid, beta-mercaptoethanol and cysteine; rats are selected and fed with feeding feed, the rats freely eat and drink water, and the rats are fed for at least 6 days; during feeding, a mixture of oteracil potassium and hypoxanthine is fed every day. The hyperuricemia rat model constructed by the invention is good in stability, and can be used for further exploring the efficacy evaluation of uric acid lowering drugs and the mechanism of organ change caused by gout.

The invention belongs to the technical field of biological medicines, and discloses application of a deep-sea butyrolactone compound in preparation of a product for preventing and / or treating hyperuricemia and / or uric acid nephropathy. The butyrolactone compound disclosed by the invention is specifically 5-acetyl-3-hydroxy-4-(4-hydroxyphenyl)-5-[4-methyl-3-(3-methylbutyl-2-ene-1-yl) benzyl] furan-2 (5H)-ketone, and the structural formula of the butyrolactone compound is shown in the description. It is proved for the first time that the butyrolactone compound has the capacity of remarkably improving hyperuricemia and uric acid nephropathy, and the blood uric acid level, the serum creatinine level and the blood urea nitrogen level of hyperuricemia mice induced by oteracil potassium and hypoxanthine and uricase knockout mice are remarkably improved; the compound can be applied to preparation of products for preventing and / or treating the hyperuricemia and / or the uric acid nephropathy, a new product is provided for prevention and treatment of the hyperuricemia and the uric acid nephropathy, and therefore the compound has a wide application prospect.

The invention discloses application of a rhizoma smilacis glabrae extract in preparation of a product for treating hyperuricemia. The content of tannin in the rhizoma smilacis glabrae extract is greater than 20%, or the rhizoma smilacis glabrae extract also contains astilbin composition components. Through systematic research and animal experiments, it is found that the rhizoma smilacis glabrae extract containing the tannin or the composition containing the tannin and astilbin has the effect of treating hyperuricemia caused by oteracil potassium and adenine and hyperuricemia induced by fructose in a multi-way and multi-target mode; the compound is effective to multiple targets including xanthine oxidase, adenosine deaminase, urate transporter and the like.

This invention provides a method for constructing a rat model of hyperuricemia, belonging to the field of animal model construction technology. SPF-grade male rats were selected and, after adaptive feeding, were administered inosine (5-15 mg / kg), potassium oxonate (150-160 mg / kg), and hypoxanthine (100-200 mg / kg). Inosine and potassium oxonate were administered intraperitoneally, while hypoxanthine was administered subcutaneously. Experimental results showed that serum uric acid levels significantly increased one hour after modeling, and the hyperuricemic state could be maintained for up to 24 hours, significantly better than traditional models. Simultaneously, serum urea nitrogen and creatinine levels did not show significant increases, indicating that the model did not cause serious kidney damage. The hyperuricemia model constructed by this invention has a rapid onset of action, a long duration of hyperuricemia, and minimal kidney damage, making it suitable for the screening and evaluation of anti-hyperuricemia drugs.

The invention relates to a lactobacillus plantarum LP-SG7, a postbiotics, a composition and application. The lactobacillus plantarum LP-SG7 provided by the invention is high in biological activity and can tolerate gastric acid and cholate. The lactobacillus plantarum LP-SG7 or the composition containing the viable bacteria of the lactobacillus plantarum LP-SG7 and the metagenic powder described in the invention can significantly reduce the content of blood uric acid, urea nitrogen and creatinine in a model mouse with oteracil potassium induced hyperuricemia, and reduce the content of xanthine oxygen in liver tissues.

The present invention relates to a composite mouse model simulating hyperuricemia exacerbated periodontitis and its establishment method and application. The establishment method comprises the following steps: step one: continuously injecting potassium oxonate into the peritoneal cavity of mice for 7 days; step two: on the 7th day, ligating a surgical thread to the maxillary second molar of the mice by using a micro needle holder; step three: continuing to continuously inject potassium oxonate into the peritoneal cavity of mice for 7 days to establish a composite mouse model simulating hyperuricemia exacerbated periodontitis. The hyperuricemia model constructed by potassium oxonate in the present invention can not only increase the uric acid level in a short period of time, but also maintain the uric acid level for a long time through continuous administration during the maintenance period. Combined with the construction of a mild and non-injurious periodontitis model, a composite mouse model of hyperuricemia exacerbated periodontitis is successfully simulated, effectively filling the gap in the lack of animal models in the research field related to hyperuricemia and periodontitis, and broadening the ideas and methods of clinical research hotspots.

The invention belongs to the technical field of animal models of human diseases, and particularly relates to a modeling method of a damp-heat type gout disease animal model. According to the damp-heat type gout disease animal model, the damp-heat type gout disease animal model adopts three methods of high-fat feeding, ethanol feeding and artificial climate box to jointly induce an animal to generate damp-heat syndrome, adopts three methods of hypoxanthine intragastric administration, oteracil potassium intraperitoneal injection and sodium urate joint injection to jointly induce the animal to generate gout disease, and combines the diseases and the syndromes; the obtained animal model can better simulate the human damp-heat gout disease, so that the animal model can be used for pharmacodynamic research or pathological mechanism research and the like.

This invention discloses two strains of *Lactobacillus reuteri* that are highly efficient at degrading nucleosides and their applications. *Lactobacillus reuteri* ( Limosilactobacillus reuteri The *Lactobacillus reuteri* strains W6-12 and W6-5, with accession numbers GDMCC No. 67938 and GDMCC No. 67937, respectively, exhibit efficient in vitro degradation of adenosine, guanosine, and inosine. In vivo, they significantly reduce serum uric acid levels in HUA broiler chickens induced by high calcium and high protein intake. Their fermented milk significantly reduces serum uric acid levels in SD rats with hyperuricemia induced by potassium hypoxanthine and hypoxanthine. This invention has been confirmed at multiple levels, including genetic and animal studies, to pose no potential harm to humans, demonstrating its safety and high efficiency.